Monoclonal Gammopathy of Undetermined Significance

All 241 patients who had been diagnosed at the Mayo Clinic with an apparently benign monoclonal gammopathy before January 1, 1971, were followed followed forward through 1992. Of primary interest was the possible development of serious plasma cell proliferative disorders, however, the advanced age of many patients makes death from other causes a significant competing risk.

Most subjects in the study were discovered incidentally in the process of being examined for other indications. The laboratory values (albumin, creatinine, etc.) may be related to the severity of those other indications, but have shown less relationship to MGUS per se.

• Subject number
• Age at first diagnosis of MGUS
• Sex: 1=male, 2=female
• Calendar year of first diagnosis of MGUS
• Type of plasma cell proliferative disorder (blank if none)
  • AM systemic amyloidosis
  • LP malignant lymphoproliferative disease
  • MA macroglobulinemia
  • MM multiple myeloma
• Time to plasma cell proliferative disorder
• Time to death or last follow-up
• Status at last follow-up: 0=alive, 1=dead
• Albumin level, at MGUS diagnosis
• Serum creatinine level, at MGUS diagnosis
• Hemoglobin level, at MGUS diagnosis
• Size of the monoclonal protien peak, at MGUS diagnosis